AC Immune SA
ACIU Nasdaq· Pharmaceutical Preparations
KIRA · Stoqly’s AI analyst, in plain words
- AC Immune SA had $4.3M of revenue in fiscal 2025, down 86.1% on the year before. Over five years, revenue changed −23.5% a year on average.
- Its operating margin was −1,940.0%, down 1,748.2 pts: of every 100 in sales, about −1,940 is left after running the business.
- AC Immune SA lost $84.8M in fiscal 2025.
- Free cash flow was −$84.4M in fiscal 2025, −1,963.7% of revenue.
Market cap
—
P/E
—
Revenue
$4.3M
Net income
−$84.8M
Free cash flow
−$84.4M
Operating margin
−1,940.0%
AC Immune SA in 30 seconds · fiscal 2025
Are sales growing?
−86.1%
No. Sales fell 86.1% last year.
Does it make a profit?
−1,971.6%
No. It lost money last year.
Does profit turn into cash?
−1,963.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
What AC Immune SA does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 13, 2026
- Legal name
- AC Immune SA
- CIK
- 0001651625
AC Immune SA · ACIU
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $4.1M | $16.5M | $31.0M | $4.3M |
| Revenue growth | −100.0% | — | 299.8% | 88.3% | −86.1% |
| Operating margin | — | −1,800.4% | −362.3% | −191.8% | −1,940.0% |
| Net income | −$79.9M | −$74.1M | −$60.4M | −$57.8M | −$84.8M |
| Net margin | — | −1,798.0% | −366.4% | −186.4% | −1,971.6% |
| Diluted EPS | −$1.06 | −$0.89 | −$0.71 | −$0.58 | −$0.84 |
| Cash | |||||
| Cash from operations | −$71.9M | −$77.0M | −$67.2M | $74.8M | −$83.3M |
| Capital expenditure | $2.9M | $1.3M | $0.9M | $0.7M | $1.1M |
| Free cash flow | −$74.8M | −$78.3M | −$68.1M | $74.1M | −$84.4M |
| FCF margin | — | −1,901.1% | −413.5% | 239.0% | −1,963.7% |
| Share buybacks | $0.0M | $0.0M | — | — | — |
| Share count change | 4.2% | 11.5% | 1.4% | 17.7% | 1.1% |
| Debt and strength | |||||
| Cash and short-term investments | $90.1M | $34.2M | $93.7M | $40.0M | $33.8M |
| Shareholders' equity | $254M | $183M | $192M | $124M | $56.6M |
| Current ratio | 10.1x | 11.2x | 9.2x | 1.7x | 1.0x |
| Interest coverage | −136.0x | −199.6x | −304.7x | −393.9x | −362.9x |
| Returns and quality | |||||
| Return on equity | −32.0% | −33.9% | −32.2% | −36.6% | −93.9% |
| Return on tangible equity | −40.1% | −57.7% | −45.9% | −84.7% | — |
| Piotroski F-score | 1 | 2 | 2 | 4 | 1 |
| Altman Z'' | 8.3 | 7.5 | 4.1 | −3.8 | −11.6 |
Insiders bought, 12 months
$0.0M
1 insider
Insiders sold, 12 months
$0.0M
1 insider
Of sales under plans
100%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
AC Immune SA · ACIU
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Source: SEC EDGAR XBRL filings (CIK 0001651625). Data updated October 24, 2026. Filed in CHF under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.